Investing Profile

Chris Garabedian

InvestorVC
Portfolio Manager, Venture (PXV Fund) at Perceptive Advisors
perceptivelife.com/team/Boston, Massachusetts
Photo of Chris Garabedian, Perceptive Advisors

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
University of Maryland Network
56 CONNECTIONS
cb
$100K - $10.0M
$1M
22
CompanyStageDateRound SizeTotal Raised
CereVasc
Series CJun 2026$85M
Series BMay 2024$70M
Series AJun 2020$44M
$200M
Zucara Therapeutics
Series BNov 2024$20M
Series AMar 2020$21M
$41M
Marea Therapeutics
Series BJun 2024$190M
$260M
Co-investors: Charles Homcy (Third Rock Ventures), Jeffrey Tong (Third Rock Ventures), Maha Katabi (Sofinnova Investments), Aaron Royston (venBio)
Delve Bio
Series AJun 2023$35M
$35M
Co-investors: Anthony Philippakis (GV (Google Ventures))
Tellus Therapeutics
Series ADec 2022$35M
SeedMay 2021$2M
$37M
Peroxitech Therapeutics
Series ADec 2022$25M
SeedMay 2021
$25M
PolyCore Therapeutics
SeedApr 2022
$500K
VivoSense
Series AMar 2022$25M
$25M
Portfolio Manager, Venture (PXV Fund) Perceptive AdvisorsPresent
Board Member Landos Biopharma, Inc.Present
Board Member Zucara Therapeutics Inc.Present
Board Member AsclepiX TherapeuticsPresent
Board Member CereVascPresent
Board Member AsclepiX Therapeutics, Inc.Present
Chairman of the Board Forge BiologicsPresent
Chairman Of The Board Forge BiologicsPresent
Board Member Delve BioPresent
Board Member Marea TherapeuticsPresent
Board Member Crystalys TherapeuticsPresent
Chairman and CEO XontogenyPresent
University of Maryland B.S. Marketing